Syk Kinase Inhibitor Molecules Targeting Protein Interaction Sites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological inhibitors of Syk kinase activity face challenges due to systemic exposure affecting various cell types, leading to potential side effects on physiological functions, necessitating the development of molecules that inhibit Syk protein interaction with natural partners rather than targeting the catalytic site.
Innovation Solution
The development of organic molecules, such as compound C-13 and functionally equivalent molecules, which inhibit the binding of antibodies or antibody fragments with Syk tyrosine kinase protein by targeting specific epitopes outside the catalytic domain, thereby preventing interaction without affecting kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacological inhibitors target the catalytic site of Syk kinase, then Syk kinase activity is inhibited, but side effects occur on various physiological functions due to systemic exposure
Solution Approach 1:
The patent extracts the inhibitory action from the catalytic site and applies it to the protein-protein interaction interface. By targeting the binding site of natural partners (such as ITAM motifs) rather than the catalytic site, the invention achieves Syk inhibition without disrupting essential physiological functions, thus resolving the contradiction between efficacy and side effects.
Solution Approach 2:
The patent applies local quality by specifically targeting a localized binding site on Syk protein where natural partners interact, rather than broadly inhibiting catalytic activity. This localized approach allows selective interference with pathological interactions while preserving normal physiological functions, reducing side effects.
2Reliability
If Syk protein interaction is inhibited, then therapeutic effect is achieved for allergic disorders, but loss of Syk function affects cell differentiation, adhesion and proliferation
Solution Approach 1:
The patent extracts the inhibitory mechanism from catalytic site blocking and applies it to the protein-protein interaction interface. By targeting the binding site of natural partners, the invention selectively disrupts pathological signaling while leaving essential Syk functions intact, thus achieving therapeutic effect without adverse effects on cell differentiation, adhesion and proliferation.
Solution Approach 2:
Instead of inhibiting Syk catalytic activity (the conventional approach), the patent inverts the strategy by inhibiting the binding of natural partners to Syk. This inversion allows the Syk protein to remain functionally active while preventing its interaction with pathological partners, thereby achieving therapeutic effect without compromising essential cellular functions.
Data Source
AI summary
The present invention relates to the C-13 molecule (methyl 2-{5-[(3-benzyl-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]-2-furyl}-benzoate) and to organic molecules functionally equivalent to the C-13 molecule, capable of inhibiting the binding of an antibody or antibody fragment with the human Syk protein tyrosine kinase, to the use of these molecules for the production of medicaments for the prevention or treatment of diseases dependent on metabolic pathways involving Syk, and also to a method for identifying such molecules.